Logo image of QNRX

QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Fundamental Analysis

NASDAQ:QNRX - Nasdaq - US74907L4095 - ADR - Currency: USD

8.7  +0.3 (+3.6%)

Fundamental Rating

1

QNRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. QNRX may be in some trouble as it scores bad on both profitability and health. QNRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year QNRX has reported negative net income.
In the past year QNRX has reported a negative cash flow from operations.
QNRX had negative earnings in each of the past 5 years.
In the past 5 years QNRX always reported negative operating cash flow.
QNRX Yearly Net Income VS EBIT VS OCF VS FCFQNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

QNRX has a worse Return On Assets (-80.64%) than 70.56% of its industry peers.
The Return On Equity of QNRX (-176.30%) is worse than 65.17% of its industry peers.
Industry RankSector Rank
ROA -80.64%
ROE -176.3%
ROIC N/A
ROA(3y)-64.6%
ROA(5y)-101.86%
ROE(3y)-126.09%
ROE(5y)-748.48%
ROIC(3y)N/A
ROIC(5y)N/A
QNRX Yearly ROA, ROE, ROICQNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

QNRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNRX Yearly Profit, Operating, Gross MarginsQNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for QNRX has been increased compared to 1 year ago.
QNRX has more shares outstanding than it did 5 years ago.
QNRX has a better debt/assets ratio than last year.
QNRX Yearly Shares OutstandingQNRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
QNRX Yearly Total Debt VS Total AssetsQNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -8.04, we must say that QNRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.04, QNRX is not doing good in the industry: 70.56% of the companies in the same industry are doing better.
QNRX has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
QNRX has a Debt to Equity ratio of 0.47. This is in the lower half of the industry: QNRX underperforms 73.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -8.04
ROIC/WACCN/A
WACCN/A
QNRX Yearly LT Debt VS Equity VS FCFQNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

QNRX has a Current Ratio of 2.57. This indicates that QNRX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.57, QNRX is not doing good in the industry: 69.48% of the companies in the same industry are doing better.
QNRX has a Quick Ratio of 2.57. This indicates that QNRX is financially healthy and has no problem in meeting its short term obligations.
QNRX's Quick ratio of 2.57 is on the low side compared to the rest of the industry. QNRX is outperformed by 67.33% of its industry peers.
Industry RankSector Rank
Current Ratio 2.57
Quick Ratio 2.57
QNRX Yearly Current Assets VS Current LiabilitesQNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

1

3. Growth

3.1 Past

QNRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.80%, which is quite impressive.
EPS 1Y (TTM)80.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

QNRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.28% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y62.04%
EPS Next 2Y35.06%
EPS Next 3Y29.28%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNRX Yearly Revenue VS EstimatesQNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
QNRX Yearly EPS VS EstimatesQNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

QNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year QNRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNRX Price Earnings VS Forward Price EarningsQNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNRX Per share dataQNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30 -40

4.3 Compensation for Growth

QNRX's earnings are expected to grow with 29.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.06%
EPS Next 3Y29.28%

More info and screens

0

5. Dividend

5.1 Amount

QNRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (6/20/2025, 8:00:02 PM)

8.7

+0.3 (+3.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners1.95%
Inst Owner Change-72.85%
Ins Owners7.08%
Ins Owner Change91.52%
Market Cap5.12M
Analysts82.5
Price Target51 (486.21%)
Short Float %9.52%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.18%
Min EPS beat(2)-5.04%
Max EPS beat(2)25.4%
EPS beat(4)3
Avg EPS beat(4)16.07%
Min EPS beat(4)-5.04%
Max EPS beat(4)37.32%
EPS beat(8)6
Avg EPS beat(8)11.09%
EPS beat(12)8
Avg EPS beat(12)11.2%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.94%
PT rev (3m)1015.25%
EPS NQ rev (1m)-17.62%
EPS NQ rev (3m)N/A
EPS NY rev (1m)15.56%
EPS NY rev (3m)-2073.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-48.85
EYN/A
EPS(NY)-14.28
Fwd EYN/A
FCF(TTM)-15.33
FCFYN/A
OCF(TTM)-15.33
OCFYN/A
SpS0
BVpS10.07
TBVpS9.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.64%
ROE -176.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.6%
ROA(5y)-101.86%
ROE(3y)-126.09%
ROE(5y)-748.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.57
Quick Ratio 2.57
Altman-Z -8.04
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.27%
EPS Next Y62.04%
EPS Next 2Y35.06%
EPS Next 3Y29.28%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.78%
OCF growth 3YN/A
OCF growth 5YN/A